• Refine your search:
  • 
    Keyword:
    
    • Clinical Sciences (4)
    • 6.1 Pharmaceuticals (3)
    • Brain Disorders (3)
    • Intellectual and Developmental Disabilities (IDD) (3)
    • Neurosciences (3)
    • Pediatric (3)
    • Psychology (3)
    • sertraline (3)
    • targeted treatment (3)
    • Autism (2)
    •   more
  • 
    Creator / Publisher:
    
    • Rajaratnam, Akash (6)
    • Schneider, Andrea (6)
    • Tassone, Flora (5)
    • Biag, Hazel Maridith B (3)
    • Chen, Yanjun (3)
    • Hagerman, Randi J (3)
    • Potter, Laura A (3)
    • Rivera, Susan M (3)
    • Afzal, Sumra (2)
    • Al Olaby, Reem R (2)
    •   more
  • 
    Year:
    
    • 2020 (1)
    • 2019 (5)
  • 
    Medium:
    
    • Online (6)
  • 
    Type:
    
    • Article (6)
  • 
    BLLDB-Access:
    • free (6)
    • subject to license (0)

Search in the Catalogues and Directories

All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year AND OR AND NOT All fields Title Creator / Publisher Keyword Year Sort by creator [A → Z]' creator [Z → A]' publishing year ↑ (asc)' publishing year ↓ (desc)' title [A → Z]' title [Z → A]' Simple Search Hits 1 – 6 of 6 1 Review of Autism Profiles and Response to Sertraline in Fragile X Syndrome-Associated Autism vs. Non-syndromic Autism; Next Steps for Targeted Treatment. Rajaratnam, Akash; Potter, Laura Axelrod; Biag, Hazel Maridith Barlahan. - : eScholarship, University of California, 2020 BASE Show details 2 Metformin treatment in young children with fragile X syndrome. Biag, Hazel Maridith B; Potter, Laura A; Wilkins, Victoria... In: Molecular genetics & genomic medicine, vol 7, iss 11 (2019) BASE Show details 3 A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. Potter, Laura A; Scholze, Danielle A; Biag, Hazel Maridith B; Schneider, Andrea; Chen, Yanjun; Nguyen, Danh V; Rajaratnam, Akash; Rivera, Susan M; Dwyer, Patrick S; Tassone, Flora; Al Olaby, Reem R; Choudhary, Nimrah S; Salcedo-Arellano, Maria J; Hagerman, Randi J. - : eScholarship, University of California, 2019 Abstract: Objective: Selective serotonin reuptake inhibitors like sertraline have been shown in observational studies and anecdotal reports to improve language development in young children with fragile X syndrome (FXS). A previous controlled trial of sertraline in young children with FXS found significant improvement in expressive language development as measured by the Mullen Scales of Early Learning (MSEL) among those with comorbid autism spectrum disorder (ASD) in post hoc analysis, prompting the authors to probe whether sertraline is also indicated in nonsyndromic ASD. Methods: The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 58 children with ASD aged 24 to 72 months. Results: 179 subjects were screened for eligibility, and 58 were randomized to sertraline (32) or placebo (26). Eight subjects from the sertraline arm and five from the placebo arm discontinued. Intent-to-treat analysis showed no significant difference from placebo on the primary outcomes (MSEL expressive language raw score and age equivalent combined score) or secondary outcomes. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events possibly related to study treatment occurred. Conclusion: This randomized controlled trial of sertraline treatment showed no benefit with respect to primary or secondary outcome measures. For the 6-month period, treatment in young children with ASD appears safe, although the long-term side effects of low-dose sertraline in early childhood are unknown. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02385799. Keyword: 6.1 Pharmaceuticals; Autism; autism spectrum disorder; Brain Disorders; Clinical Research; Clinical Sciences; Clinical Trials and Supportive Activities; controlled trial; Intellectual and Developmental Disabilities (IDD); Mental Health; Neurosciences; nonsyndromic autism spectrum disorder; Pediatric; Psychology; Public Health and Health Services; sertraline; targeted treatment URL: https://escholarship.org/uc/item/4vg8m00v BASE Hide details 4 A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder. Potter, Laura A; Scholze, Danielle A; Biag, Hazel Maridith B. - : eScholarship, University of California, 2019 BASE Show details 5 A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder Potter, Laura A.; Scholze, Danielle A.; Biag, Hazel Maridith B.. - : Frontiers Media S.A., 2019 BASE Show details 6 Metformin treatment in young children with fragile X syndrome Biag, Hazel Maridith B.; Potter, Laura A.; Wilkins, Victoria. - : John Wiley and Sons Inc., 2019 BASE Show details

Mobile view All Catalogues UB Frankfurt Linguistik 0 IDS Mannheim 0 OLC Linguistik 0 UB Frankfurt Retrokatalog 0 DNB Subject Category Language 0 Institut für Empirische Sprachwissenschaft 0 Leibniz-Centre General Linguistics (ZAS) 0 Bibliographies BLLDB 0 BDSL 0 IDS Bibliografie zur deutschen Grammatik 0 IDS Bibliografie zur Gesprächsforschung 0 IDS Konnektoren im Deutschen 0 IDS Präpositionen im Deutschen 0 IDS OBELEX meta 0 MPI-SHH Linguistics Collection 0 MPI for Psycholinguistics 0 Linked Open Data catalogues Annohub 0 Online resources Link directory 0 Journal directory 0 Database directory 0 Dictionary directory 0 Open access documents BASE 6 Linguistik-Repository 0 IDS Publikationsserver 0 Online dissertations 0 Language Description Heritage 0